ACTU

Actuate Therapeutics, Inc. - Common stock (ACTU)

About Actuate Therapeutics, Inc. - Common stock (ACTU)

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.

Details

Daily high

$9.23

Daily low

$8.82

Price at open

$9.08

52 Week High

$11.73

52 Week Low

$5.51

Market cap

176.8M

Dividend yield

0.00%

Volume

33,666

Avg. volume

62,083

P/E ratio

-6.44

Actuate Therapeutics, Inc. - Common stock News